--- title: "Weekly Recap | iQIYI -4.35%, most brokers rate it buy" type: "News" locale: "en" url: "https://longbridge.com/en/news/298098791.md" description: "iQIYI (IQ) fell 4.35% this week to close at $0.88, while the S&P 500 rose 0.09%, leaving the stock about 4.44 percentage points behind the benchmark. The week opened with a push toward $0.9697 on Monday before fading through Tuesday and hitting $0.8601 on Wednesday, the lowest level of the period. Thursday brought a partial bounce to $0.8825, but Friday slipped back to $0.88 as the stock settled near the lower end of the week’s range." datetime: "2026-09-05T07:08:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/298098791.md) - [en](https://longbridge.com/en/news/298098791.md) - [zh-HK](https://longbridge.com/zh-HK/news/298098791.md) generator: "portal-rs" --- # Weekly Recap | iQIYI -4.35%, most brokers rate it buy ## The Week iQIYI (IQ) fell 4.35% this week to close at $0.88, while the S&P 500 rose 0.09%, leaving the stock about 4.44 percentage points behind the benchmark. The week opened with a push toward $0.9697 on Monday before fading through Tuesday and hitting $0.8601 on Wednesday, the lowest level of the period. Thursday brought a partial bounce to $0.8825, but Friday slipped back to $0.88 as the stock settled near the lower end of the week’s range. ## Key Events The week’s news flow centred on broader moves in US-listed Chinese ADRs and iQIYI’s own price action. Overnight on 1 September, most US-listed Chinese ADRs fell, and iQIYI traded lower in sympathy. On 2 September the stock touched a new 52-week low, drawing attention to the downside move. Mixed signals across tech and healthcare sectors during a dense earnings stretch added to the cautious tone around growth names. There were no major company-specific announcements on products, earnings, or regulation during the period, leaving the narrative driven mainly by market-wide pullback pressure. ## Analyst Ratings Coverage totals 20 institutions. Among them, 9 rate it buy or overweight (7 buy, 2 overweight), 10 hold, and 1 sell. The consensus rating is buy, with a consensus target price near $1.397, representing roughly 58.75% upside from the latest close. The target range is wide, from $0.500 to $2.541, pointing to considerable dispersion in views. Within the film and entertainment industry, iQIYI ranks 8th out of 43 names, a relatively strong position. ## The Week Ahead The coming week brings a heavy slate of US macro data. On Tuesday 8 September, the NFIB small business optimism index is due, with a prior read of 99.8. Thursday 10 September is particularly busy, with initial jobless claims, final demand PPI, core PPI, existing home sales, and the 10-year Treasury auction all scheduled. These releases could shift risk appetite toward Chinese ADRs and growth stocks, and iQIYI’s sensitivity to macro sentiment will be worth watching. ## In Short iQIYI pulled back to a lower band this week, contrasting with the S&P 500’s slight gain. The consensus rating remains buy and the consensus target sits well above spot, yet the target spread is wide. The latest session’s flow shows large-lot money turning net seller, while small and medium flows lean more balanced. The next test is whether macro data landing next week can steady risk sentiment, and whether the $0.86 to $0.88 zone holds as a floor. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [IQ.US](https://longbridge.com/en/quote/IQ.US.md) ## Related News & Research - [iQIYI Revives 90-Year-Old Lost Film with NadouPro, Shortlisted for the AI Unit at the Golden Rooster Awards | IQ Stock News](https://longbridge.com/en/news/304616805.md) - [iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production](https://longbridge.com/en/news/303881689.md) - [Datavault AI and Biochar Now Combine Insured Carbon Removal Credits with Patented Tokenization Technology](https://longbridge.com/en/news/304846048.md) - [AISP: $16.7M 9M revenue, record backlog and pipeline, and Praxis outcome-priced AI expansion](https://longbridge.com/en/news/304879953.md) - [Coca-Cola Stock Keeps Setting Records. I'm Still Not Buying It.](https://longbridge.com/en/news/304831218.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**